Document is current
Any future updates will be listed below
-
Authors
Wong, Marie https://orcid.org/0000-0003-0066-6606
Mayoh, Chelsea https://orcid.org/0000-0002-6398-3046
Lau, Loretta M. S.
Khuong-Quang, Dong-Anh https://orcid.org/0000-0001-6305-7790
Pinese, Mark https://orcid.org/0000-0001-5078-6687
Kumar, Amit https://orcid.org/0000-0003-4771-0627
Barahona, Paulette
Wilkie, Emilie E. https://orcid.org/0000-0002-6008-8193
Sullivan, Patricia https://orcid.org/0000-0002-4886-8883
Bowen-James, Rachel https://orcid.org/0000-0002-9062-3644
Syed, Mustafa https://orcid.org/0000-0002-8759-7537
Martincorena, Iñigo
Abascal, Federico
Sherstyuk, Alexandra
Bolanos, Noemi A. https://orcid.org/0000-0001-6880-5428
Baber, Jonathan
Priestley, Peter https://orcid.org/0000-0002-4939-7104
Dolman, M. Emmy M.
Fleuren, Emmy D. G.
Gauthier, Marie-Emilie
Mould, Emily V. A.
Gayevskiy, Velimir
Gifford, Andrew J.
Grebert-Wade, Dylan
Strong, Patrick A.
Manouvrier, Elodie
Warby, Meera
Thomas, David M. https://orcid.org/0000-0002-2527-5428
Kirk, Judy
Tucker, Katherine
O’Brien, Tracey
Alvaro, Frank
McCowage, Geoffry B.
Dalla-Pozza, Luciano
Gottardo, Nicholas G.
Tapp, Heather
Wood, Paul
Khaw, Seong-Lin
Hansford, Jordan R.
Moore, Andrew S. https://orcid.org/0000-0001-8062-1779
Norris, Murray D.
Trahair, Toby N.
Lock, Richard B.
Tyrrell, Vanessa
Haber, Michelle
Marshall, Glenn M.
Ziegler, David S. https://orcid.org/0000-0001-7451-7916
Ekert, Paul G. https://orcid.org/0000-0002-2976-8617
Cowley, Mark J. https://orcid.org/0000-0002-9519-5714
-
Funding
Funding for this research was provided by:
Cancer Australia (APP1165556)
- License Information
-
More Information
Article History
Received: 4 February 2020
Accepted: 20 August 2020
First Online: 5 October 2020
Competing interests
: All authors, except P.G.E., S.-L.K. and D.S.Z., declare that they have no competing interests as defined by Nature Research or other interests that might be perceived to influence the interpretations of the article. D.S.Z. has received funding for travel and consulting from Bayer. P.G.E. and S.-L.K. are recipients of a share in milestone and royalty payments paid to the Walter and Eliza Hall Institute of Medical Research for the development of venetoclax.
